Pilot trial protocol: glycation-lowering supplement in postmenopausal women
The GRACE protocol describes a planned six-month randomized, double-blind, placebo-controlled pilot trial in postmenopausal women aged 45–65 with elevated adiposity and elevated HbA1c, testing whether GLYLO lowers circulating AGEs and methylglyoxal; results are not yet reported. [1]
Automatic summary · not editorially reviewed
The key findings
GRACE is described as a randomized, double-blind, placebo-controlled pilot study in postmenopausal women aged 45–65 with elevated adiposity and elevated HbA1c. [1]
GLYLO is a five-compound glycation-lowering formulation; preclinical studies suggest it reduces AGE burden, but human relevance is unknown. [1]
The abstract reports a planned trial design and registry identifier, not enrollment numbers or results. [1]
The source at a glance
- Study type / format
- Protocol abstract for a randomized, double-blind, placebo-controlled pilot trial
- Population / context
- Postmenopausal women aged 45–65 years with elevated adiposity and elevated HbA1c
- Summary based on
- Study abstract
- Original publication
- April 23, 2026
Planned GRACE trial in postmenopausal women
The abstract presents a protocol, not results. GRACE is described as a randomized, double-blind, placebo-controlled pilot study in postmenopausal women aged 45–65 years with elevated adiposity (BMI ≥ 25 kg/m² or waist circumference ≥88 cm) and elevated HbA1c (5.5–6.4%). It is designed to test whether six months of GLYLO supplementation lowers circulating AGEs and methylglyoxal. The authors frame this as addressing a gap in geroscience: whether targeting glycation can mitigate early metabolic and functional decline after menopause.
Supporting source [1]
GLYLO formulation and preclinical rationale
GLYLO is described as a five-compound glycation-lowering formulation containing alpha-lipoic acid, nicotinamide, pyridoxine, benfotiamine and piperine. Preclinical studies are said to show that it reduces AGE burden and improves metabolic health. The abstract states that its relevance for humans is unknown, which is the reason for the trial.
Supporting source [1]
Secondary endpoints and abstract-only scope
Secondary and exploratory endpoints listed are HOMA-IR, body composition, reproductive hormones, cognitive and physical function, retinal aging and systemic inflammation. The abstract gives no enrollment numbers, no follow-up results and no outcome data; it reports only the planned design and the ClinicalTrials.gov identifier NCT06813261. Whether GLYLO lowers AGEs or methylglyoxal in humans, and whether any such change affects the other endpoints, remains untested here.
Supporting source [1]
How to interpret this
This is an abstract of a study protocol; the full text was not reviewed. No results, enrollment numbers or follow-up data are reported, and the preclinical findings do not establish human benefit.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Vineeta Tanwar, Pankaj Kapahi, John C. Newman, Brianna Stubbs · doi.org · April 23, 2026